Forte Biosciences (FBRX) Share-based Compensation Growth (3y) (2019 - 2026)
Powered by 
Analysis
Forte Biosciences (FBRX) Share-based Compensation Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 17.49% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.55% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 30.98% |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | 170.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 170.01% |
| Mar 31, 2026 | 150.87% |
| Dec 31, 2025 | 24.61% |
| Sep 30, 2025 | 81.37% |
| Jun 30, 2025 | 2.81% |
| Mar 31, 2025 | 6.47% |
| Dec 31, 2024 | -17.43% |
| Sep 30, 2024 | -19.37% |
| Jun 30, 2024 | 52.11% |
| Mar 31, 2024 | 64.97% |
| Sep 30, 2023 | 36.53% |
| Jun 30, 2023 | 43.49% |
| Mar 31, 2023 | 133.87% |
| Dec 31, 2022 | 202.72% |
| Sep 30, 2022 | 131.15% |
| Jun 30, 2022 | 131.44% |
| Mar 31, 2022 | -1.27% |
| Dec 31, 2021 | -10.90% |
| Sep 30, 2021 | -7.82% |
| Jun 30, 2021 | -5.84% |